Ocular Therapeutix (NASDAQ:OCUL) Insider Sells $15,235.60 in Stock

by · The Cerbat Gem

Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Free Report) insider Sanjay Nayak sold 1,858 shares of Ocular Therapeutix stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $8.20, for a total transaction of $15,235.60. Following the completion of the transaction, the insider owned 328,795 shares in the company, valued at approximately $2,696,119. This represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ocular Therapeutix Stock Performance

NASDAQ OCUL traded up $0.61 during trading on Thursday, reaching $9.15. The company’s stock had a trading volume of 3,382,545 shares, compared to its average volume of 5,029,148. The company has a debt-to-equity ratio of 0.12, a quick ratio of 14.73 and a current ratio of 14.81. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -6.27 and a beta of 0.93. Ocular Therapeutix, Inc. has a twelve month low of $6.23 and a twelve month high of $16.44. The business’s fifty day moving average price is $8.78 and its 200-day moving average price is $10.24.

Analyst Ratings Changes

OCUL has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, May 5th. Jefferies Financial Group restated a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Royal Bank Of Canada restated an “outperform” rating and set a $30.00 target price on shares of Ocular Therapeutix in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Tuesday, April 21st. Finally, Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.78.

Read Our Latest Report on OCUL

Institutional Trading of Ocular Therapeutix

Institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC lifted its holdings in shares of Ocular Therapeutix by 124.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,242 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 1,242 shares in the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $31,000. Hilton Head Capital Partners LLC purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $42,000. Atlas Capital Advisors Inc. purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $61,000. Finally, State of Wyoming purchased a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $78,000. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

(Get Free Report)

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.

Recommended Stories